Redeye continues to view Scibase as a long-term growth case after the Q4 report earlier today. The company has laid an excellent foundation for strong future growth. There are several catalysts for the company during 2021. The CPT III codes and MDR are just two of those. After a report much in line with our expectations and a promising outlook, we maintain our base case's motivated value at SEK 9 per share.